Skip to main content
. 2025 Jul 11;15(16):7925–7939. doi: 10.7150/thno.114467

Figure 7.

Figure 7

Safety evaluation of M1M@Ds in vivo. (A) The body weight and (B) organs index of mice after different treatments on day 9. (n = 5) (C) Photo and (D) Hemolysis ratio of mice after different treatments on day 9. (E) H&E staining of mice after different treatments on day 9. (F) The concentration of the white blood cells (WBC), the red blood cells (RBC), and the platelet (PLT) in blood of mice after different treatments on day 9. (n = 3) (G) The concentration of the alanine transaminase (ALT), the aspartate transaminase (AST), the blood urea nitrogen (BUN), the creatinine (CREA), the uric acid (UA), and the total bilirubin (TBIL) in serum of mice after different treatments on day 9. (n = 5), ns (not significant, p > 0.05).